MSME (Udyam registered) Ministry of MSME
- Category
- Small (2024-25)
- Udyam number
- UDYAM-MH-18-0114288
SRS Pharmaceuticals Private Limited - pharma in Mumbai, Maharashtra, India. FY 2026 financials & compliance.
Revenue · FY 2025
₹88.26 Cr
▼ 10% YoY
Net loss · FY 2025
₹12.52 Cr
Net margin -14.2%
EBITDA · FY 2025
-₹3.28 Cr
EBITDA margin -3.7%
Authorised capital
₹5 Cr
Registered with MCA
Paid-up capital
₹5 Cr
Issued & subscribed
Open charges
₹18.75 Cr
Satisfied ₹12 Cr
Company age
25 yrs
Est. 2001
Employees · EPFO
87
Provident fund records
About SRS Pharmaceuticals Private Limited
Data last updated:
SRS Pharmaceuticals Private Limited is a private limited company based in Mumbai, Maharashtra, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 27 March 2001 and has been in existence for over 25 years.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN U24239MH2001PTC131384. Its GSTIN is 27AAFCS4633P1ZT (Maharashtra). The company holds 2 GST registrations, all of them active.
The company has an authorised share capital of ₹5 Cr and a paid-up capital of ₹5 Cr. It is led by directors including Pooja Ketan Deshpande and Suchet Shyamsunder Rastogi.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at 504 Marathon Max Bldg No.2 Mulund – Goregoan Link L.B.S Marg Mulund West Mumbai Mh 400080, In, Maharashtra, India – 400080.
As per the financials filed for FY 2025, the company reported a revenue of ₹88.26 Cr, a decline of 10% compared to the previous year. For the same year it recorded a net loss of ₹12.52 Cr (net margin -14.2%) and EBITDA of -₹3.28 Cr (EBITDA margin -3.7%). Revenue has grown at a compounded annual rate (CAGR) of 31% over three years and 4% over five years.
The company has about 87 employees on its provident fund (EPFO) records. Its group structure includes 1 subsidiary.
The company is associated with 1 brand: SRS Life Sciences. As per MCA filings, the company has open charges of ₹18.75 Cr and satisfied charges of ₹12 Cr on record. Court records list 17 cases involving the company, including 7 filed by the company and 10 filed against it; 3 cases are pending. The company has 1 deal on record (1 secondary share transfer); the latest was in March 2007. Its 8 peer companies in the Pharma industry (Formulations, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 5 larger and 3 smaller; the largest is Evertogen Life Sciences Limited with revenue of ₹89.28 Cr. The company has 9 MSME Form 1 returns on record between 2019 and 2024, listing 221 overdue payments to 47 micro and small suppliers.
SRS Pharmaceuticals Private Limited is registered as a small enterprise under the Udyam registration framework (Reg. No. UDYAM-MH-18-0114288). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website srslife.com.
Company details
CIN U24239MH2001PTC131384
Registration Number 131384
Incorporation Date 27 March 2001
ROC Mumbai
Listing Status Unlisted
Company Status Active
Date of Last AGM 30 September 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
MSME Classification Small
Udyam Registration UDYAM-MH-18-0114288
Key People
Pooja Ketan Deshpande Director Suchet Shyamsunder Rastogi Director Anuradha Ganesh Naik Additional Director Recognitions & Rankings of SRS Pharmaceuticals
Contact details
SRS Pharmaceuticals Private Limited's registered office is in Mumbai, Maharashtra. Its website is srslife.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered Address504 Marathon Max Bldg No.2 Mulund – Goregoan Link L.B.S Marg Mulund West Mumbai Mh 400080, In, Maharashtra, India – 400080
- IndustryPharma, Drug Formulation & Development
To see the full contact details of SRS Pharmaceuticals Private Limited, buy the company report.
Comprehensive company report
SRS Pharmaceuticals Private Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
SRS Pharmaceuticals operates one associated brand: SRS Life Sciences. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Develops therapies and diagnostics to address diseases in emerging markets. | srslife.com |
Business activity
The main business activity of SRS Pharmaceuticals is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of SRS Pharmaceuticals Private Limited, buy the company report.
Financials of SRS Pharmaceuticals Private Limited
FY 2025 filings availableSRS Pharmaceuticals Private Limited reported revenue of ₹88.26 Cr (down 10% YoY) for FY 2025.
Revenue · FY 2025
₹88.26 Cr ▼ 10%
Net loss · FY 2025
₹12.52 Cr margin -14.2%
EBITDA · FY 2025
-₹3.28 Cr margin -3.7%
Compounded Annual Growth Rate (CAGR)
Revenue CAGR growth
1 year
▼ 10%
3 years · compounded
▼ 31%
5 years · compounded
▲ 4%
EBITDA CAGR growth
1 year
▼ 161%
3 years · compounded
▼ 26%
5 years · compounded
▼ 19%
Revenue fell 10% in the latest year, but over five years it has grown at a compounded annual rate (CAGR) of 4%. EBITDA fell 161% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | -₹3.28 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | -₹12.52 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | -3.7% | ||||
| Net Profit Margin | -14.2% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of SRS Pharmaceuticals Private Limited, buy the company report.
Board of directors of SRS Pharmaceuticals Private Limited
SRS Pharmaceuticals has 3 current directors and 7 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Pooja Ketan Deshpande | Director | 10 Jun 2024 | 2 Years 4 Months | Current |
| Suchet Shyamsunder Rastogi Also directs: SRS Unistraw Private Limited, Clesstra Healthcare Private Limited, Unitex Tenamyd Canada Private Limited and 3 more | Director | 27 Mar 2001 | 25 Years 6 Months | Current |
| Anuradha Ganesh Naik | Additional Director | 30 Apr 2025 | 1 Years 5 Months | Current |
Peer comparison
SRS Pharmaceuticals Private Limited is compared with the 8 companies closest to it by revenue in the Pharma industry (Formulations, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Evertogen Life Sciences Limited | ₹89.28 Cr (FY 2024) | 51.0% | Hyderabad, Telangana, India | |||
| U S Pharma (India) Private Limited | ₹89.26 Cr (FY 2025) | 421.0% | Mumbai, Maharashtra, India | |||
| Gnosis Pharmaceuticals Private Limited | ₹88.76 Cr (FY 2024) | 18.0% | New Delhi, Delhi, India | |||
| Martin & Brown Bio-Sciences Private Limited | ₹88.52 Cr (FY 2025) | 75.0% | Nalagarh, Himachal Pradesh, India | |||
| Ravian Life Science Private Limited | ₹88.41 Cr (FY 2025) | 2.0% | Haridwar, Uttarakhand, India | |||
| SRS Pharmaceuticals Private Limitedthis company | ₹88.26 Cr (FY 2025) | -₹12.52 Cr | -14.2% | -10.0% | 87 | Mumbai, Maharashtra, India |
| Appasamy Ocular Devices Private Limited | ₹87.93 Cr (FY 2022) | 60.0% | Chennai, Tamil Nadu, India | |||
| BDH Industries Limited | ₹87.41 Cr (FY 2024) | 16.0% | Mumbai, Maharashtra, India | |||
| Vidacare Medica Private Limited | ₹87.17 Cr (FY 2025) | -13.0% | Mumbai, Maharashtra, India |
To see the full peer comparison of SRS Pharmaceuticals Private Limited, buy the company report.
Auditor
SRS Pharmaceuticals Private Limited is audited by M.Sheth & Co. for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| M.Sheth & Co. | FY 2023 | 116371W |
Shareholding
The shareholding of SRS Pharmaceuticals Private Limited is on record for 5 financial years, the latest being FY 2023, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of SRS Pharmaceuticals Private Limited, buy the company report.
Charges & borrowings
Open charges
₹18.75 Cr
Satisfied charges
₹12 Cr
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 07 Nov 2025 | 101195938 | Hdfc Bank Limited | ₹75 Lakh | Open | |
| 03 Sep 2024 | 100984066 | Hdfc Bank Limited | ₹10 Cr | Open | |
| 15 Dec 2009 | 10191724 | Standard Chartered Bank | ₹8 Cr | Open | |
| 16 Sep 2015 | 10591262 | Standard Chartered Bank | ₹15 Lakh | Satisfied | |
| 06 Jan 2005 | 90149601 | Standard Chartered Bank | ₹11.25 Cr | Satisfied |
To see the full charge records of SRS Pharmaceuticals Private Limited, buy the company report.
Total charge records: 6 View all charges
Deals & funding
SRS Pharmaceuticals Private Limited has 1 deal on record (1 secondary share transfer); the latest was in March 2007.
Total deals
1
Secondary share transfer
1
Deals on record (1 of 1)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Mar 2007 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: an individual |
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
SRS Pharmaceuticals Private Limited has 17 court cases on record: 7 filed by SRS Pharmaceuticals, 10 filed against it. 3 cases are pending and 14 are disposed.
Total cases
17
Filed by the company
7
Filed against the company
10
Pending
3
Disposed
14
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 10 | 5 | 1 |
| District courts | 5 | 3 | 2 |
| NCLT | 2 | 2 | 0 |
Cases on record (5 of 17)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, Vadodara, Gujarat | Commercial matter | Filed against the company by Comed Chemicals Ltd. | Pending |
| District court, Solan, Himachal Pradesh | Civil suit | Filed by the company against Comed Chemicals Ltd. | Disposed |
| Bombay High Court | Court case (CARBP) | Filed by the company against Adkure Technologies Pvt Ltd and 2 Ors | Disposed |
| District court, Vadodara, Gujarat | Court case (CMA SC) | Filed against the company by Comed Chemicals Ltd | Disposed |
| District court, Vadodara, Gujarat | Court case (SPCS) | Filed against the company by Comed Chemicals Ltd. | Disposed |
To see the full case history of SRS Pharmaceuticals Private Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
SRS Pharmaceuticals Private Limited has 9 MSME Form 1 returns on record between 2019 and 2024, listing 221 overdue payments to 47 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 47)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| Newspack Logistics Private Limited | |||
| Cleanchem Laboratories LLP | |||
| an individual supplier | |||
| QBD Research and Development Lab Private Limited | |||
| SFC Cold Chain Logistics Private Limited |
To see the full MSME payment records of SRS Pharmaceuticals Private Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Group structure & subsidiaries
SRS Pharmaceuticals has 1 subsidiary company. This group structure data is as of FY 2023. The table lists each entity with its relationship and holding.
1
Subsidiary companies
Key subsidiaries
| Company Name | CIN | Shares held |
|---|---|---|
| SRS Formulations Private Limited | U74999MH2014PTC255945 |
To see the full group structure of SRS Pharmaceuticals Private Limited, buy the company report.
Employees & EPFO
SRS Pharmaceuticals Private Limited has a workforce of 87 employees on its EPFO records as of Mar 28, 2024, across 1 active EPFO establishment.
Employee count
87
Active EPFO establishments
1
Employee growth
33.85%
GST
SRS Pharmaceuticals has 2 GST registrations: 2 active.
Total GSTINs
2
Active
2
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AAFCS4633P1ZT | Maharashtra | Active | 01 Jul 2017 |
| 27AAFCS4633P2ZS | Maharashtra | Active | 04 Apr 2023 |
To see the full GST registrations and return filing status of SRS Pharmaceuticals Private Limited, buy the company report.
Recent activity
SRS Pharmaceuticals Private Limited has 9 board changes on record since 2001: 3 appointments and 6 cessations. The latest: Anuradha Ganesh Naik was appointed as Additional Director on 30 Apr 2025.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 0.75 Cr with Charge ID 101195938 was registered on 07 Nov 2025.
AGM
Srs Pharmaceuticals Private Limited last Annual general meeting of members was held on 30 Sep 2025 as per latest MCA records.
Charges
A charge registered on 16 Sep 2015 via Charge ID 10591262 with Standard Chartered Bank was fully satisfied on 12 Sep 2025.
Charges
A charge registered on 06 Jan 2005 via Charge ID 90149601 with Standard Chartered Bank was fully satisfied on 12 Sep 2025.
Appointed
Anuradha Ganesh Naik was appointed as Additional Director.
Filing
Srs Pharmaceuticals Private Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Mumbai.
Ceased
Pooja Ketan Deshpande ceased to be Additional Director.
Ceased
Sangeeta Anand Gamre ceased to be Additional Director.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 10.00 Cr with Charge ID 100984066 was registered on 03 Sep 2024.
Appointed
Pooja Ketan Deshpande was appointed as Director.
Ceased
Rajan Dubey ceased to be Additional Director.
Ceased
Ratnakar Pandarinath Mehendre ceased to be Director.
10 earlier events are in the company report.
Frequently asked questions
SRS Pharmaceuticals is an active private limited company based in Mumbai, Maharashtra, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 27 March 2001 (25+ years old) and is registered under CIN U24239MH2001PTC131384.
SRS Pharmaceuticals has 3 current directors:
- Pooja Ketan Deshpande - Director
- Suchet Shyamsunder Rastogi - Director
- Anuradha Ganesh Naik - Additional Director
The latest financial statements of SRS Pharmaceuticals on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of SRS Pharmaceuticals is 27AAFCS4633P1ZT, registered in Maharashtra. The company has 2 GST registrations in all, of which 2 are active. Other active GSTINs include 27AAFCS4633P2ZS (Maharashtra).
The CIN (Corporate Identification Number) of SRS Pharmaceuticals is U24239MH2001PTC131384. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
SRS Pharmaceuticals has 17 court cases on record: 7 filed by the company and 10 filed against it. 3 are pending. Most are in the high courts.
SRS Pharmaceuticals was incorporated on 27 March 2001, making it 25+ years old. It is registered with the Registrar of Companies, Mumbai.
SRS Pharmaceuticals has 1 deal on record (1 secondary share transfer); the latest was in March 2007.
The peers of SRS Pharmaceuticals by revenue are Evertogen Life Sciences Limited, U S Pharma (India) Private Limited, Gnosis Pharmaceuticals Private Limited, Martin & Brown Bio-Sciences Private Limited, Ravian Life Science Private Limited and 3 more, all in the Pharma industry (Formulations, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Anuradha Ganesh Naik was appointed as Additional Director on 30 Apr 2025. Pooja Ketan Deshpande ceased to be Additional Director on 29 Sep 2024. Sangeeta Anand Gamre ceased to be Additional Director on 29 Sep 2024. SRS Pharmaceuticals has 9 board changes on record in total.
Yes, SRS Pharmaceuticals is registered as a small enterprise under Udyam registration (number: UDYAM-MH-18-0114288).
SRS Pharmaceuticals has 9 MSME Form 1 returns on record between 2019 and 2024, listing 221 overdue payments to 47 micro and small suppliers. The latest return was filed on 30 Apr 2024.